Login
uniQure NASDAQ: QURE
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands.
| Name | uniQure |
| Ticker | QURE |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Price | 41.68 |
| 52W Low/High | 37.13 / 74.62 |
| Market cap | 1.8 B |
| 1Y Total Return |
-9.17%
Average |
| 1Y Volatility |
63.35%
More Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands.
Details
| Ticker | QURE |
| Name | uniQure |
| ISIN | NL0010696654 |
| CUSIP | |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Gene Editing - Cell Therapies |
| Country | Netherlands |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 9/17/20
| Close Price | 41.68 |
| 52W Low/High | 37.13 / 74.62 |
| Market cap | 1.8 B |
| 1Y Total Return |
-9.17%
Average |
| 1Y Volatility |
63.35%
More Risk |
| Beta | 1.78 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -2,553.3% |
| Cash from Op. / Cur. Liabilities | -3.72 |
| Diluted Earnings / Share | -3.14 |
| ROE | - |
| ROIC | -303.3% |
| Price / Revenue | 348.4 |
| Price / Book | 7.0 |
| Price / CF | -16.7 |
| Current Ratio | 10.7 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | 0.27 |
| in Mils USD |
rolling-year up to June
|
|||||
|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Revenue |
5
|
8
|
11
|
25
|
-
|
|
| Gross Profit |
5
|
8
|
11
|
25
|
-
|
|
| R&D |
104
|
84
|
74
|
70
|
-
|
|
| EBITDA |
-125
|
-88
|
-68
|
-61
|
-
|
|
| Operating Income |
-140
|
-106
|
-89
|
-71
|
-
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
|
| per Share | ||||||
| Diluted avg Shares |
44
|
38
|
36
|
26
|
-
|
|
| EPS exc. Extra |
-3.14
|
-2.75
|
-2.47
|
-2.82
|
-
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Total Assets |
385
|
253
|
309
|
158
|
-
|
|
| Cash, Eq & Invt ShortTerm |
314
|
184
|
259
|
104
|
-
|
|
| Total Current Assets |
320
|
189
|
263
|
111
|
-
|
|
| Total Non-Current Assets |
66
|
65
|
46
|
47
|
-
|
|
| Intangibles |
8
|
6
|
11
|
9
|
-
|
|
| Total Liabilities |
120
|
121
|
90
|
131
|
-
|
|
| Total Current Liabilities |
30
|
23
|
31
|
23
|
-
|
|
| Long Term Debt |
90
|
98
|
59
|
108
|
-
|
|
| Shareholder equity |
266
|
132
|
218
|
27
|
-
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Cash from Operations |
-111
|
-89
|
-71
|
-65
|
-
|
|
| Depreciation |
7
|
12
|
6
|
7
|
-
|
|
| Cash from Investing |
-9
|
-4
|
-5
|
-16
|
-
|
|
| Capex |
7
|
3
|
3
|
15
|
-
|
|
| Cash from Financing |
249
|
20
|
231
|
1
|
-
|
|
| Stock Issued |
249
|
5
|
230
|
1
|
-
|
|
| Debt (LT) Issued |
0
|
15
|
0
|
0
|
-
|
|
| Free Cash Flow |
-124
|
-97
|
-55
|
-
|
-
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
10.7
|
8.1
|
8.4
|
4.8
|
-
|
|
| Financial Leverage D/E |
0.27
|
0.54
|
0.10
|
0.75
|
-
|
|
| Return on Capital Avg |
-303.3%
|
-314.8%
|
-307.8%
|
-452.1%
|
-
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available